Neurocrine Bio. price target raised to $145 from $140 at Mizuho

Published 31/07/2025, 14:46
Neurocrine Bio. price target raised to $145 from $140 at Mizuho

Investing.com - Mizuho (NYSE:MFG) raised its price target on Neurocrine Bio. (NASDAQ:NBIX) to $145.00 from $140.00 on Thursday, while maintaining a Neutral rating on the stock. The biotech company, currently valued at $13.1 billion, has demonstrated strong revenue growth of 21.7% over the last twelve months.

The price target increase follows Neurocrine’s second-quarter 2025 results, which Mizuho described as "solid." The company’s Ingrezza medication performed slightly ahead of sell-side expectations, while Crenessity outperformed both sell-side and buy-side targets. According to InvestingPro data, the company maintains a "GREAT" financial health score, with liquid assets exceeding short-term obligations.

Despite these positive results, Neurocrine lowered its 2025 Ingrezza guidance by $25 million at the midpoint, which Mizuho suggested might explain "modest weakness" in the stock as some investors had expected stronger Ingrezza performance.

Mizuho maintained its 2025 Ingrezza sales forecast, which aligns with the midpoint of Neurocrine’s new guidance. The firm significantly increased its 2025 sales forecast for Crenessity from $91 million to $223 million, citing "better-than-expected and strong adoption trends" with 664 new patient start forms in the second quarter.

The firm’s Neutral rating remains unchanged, with Mizuho citing valuation as the primary factor for maintaining this position.

In other recent news, Neurocrine Biosciences reported impressive financial results for the second quarter of 2025, significantly exceeding analysts’ expectations. The company achieved earnings per share of $1.65, which was a notable increase over the projected $0.96, marking a surprise of 71.88%. Revenue also surpassed forecasts, reaching $687.5 million compared to the anticipated $653.32 million, a 5.23% increase. Additionally, BMO Capital raised its price target for Neurocrine Biosciences to $124 from $115, while maintaining a Market Perform rating. This adjustment reflects higher projected revenues for Crenessity, following a strong launch that exceeded consensus expectations by 122%. These developments highlight the company’s recent successes and positive performance in the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.